WATERTOWN, Mass.–(BUSINESS WIRE)–Tarveda
Therapeutics®, Inc., a clinical stage biopharmaceutical company
discovering and developing a new class of potent and selective miniature
drug conjugates (Pentarins®) for the treatment of patients with a wide
range of solid tumor malignancies, today announced that Drew Fromkin,
President and Chief Executive Officer, will present at the 2019 BIO
International Convention occurring June 3-6, 2019 in Philadelphia, PA.
The presentation will take place on Wednesday, June 5, 2019 at 2:00 PM
ET in Theater 3 in the Pennsylvania Convention Center.
Mr. Fromkin will provide an overview of the Company’s Pentarin platform.
Pentarins are precision oncology medicines that are designed to rapidly
penetrate solid tumors, selectively bind to the desired tumor targets,
and accumulate their anti-cancer payloads in the tumors while minimizing
exposure of healthy tissues. Mr. Fromkin will also discuss Tarveda’s two
clinical stage programs including PEN-866, which is the first miniature
drug conjugate from Tarveda’s Heat Shock Protein 90 (HSP90) binding
conjugate platform. PEN-866 is currently being evaluated in an ongoing
Phase 1/2a clinical trial in patients with advanced solid tumors.
PEN-221 is currently being evaluated in a Phase 1/2a clinical trial in
somatostatin receptor 2 (SSTR2) positive neuroendocrine tumors and is
designed to rapidly penetrate deep into solid tumors where it is highly
selective for SSTR2 and accumulates its potent DM1 payload.
To schedule a meeting with Tarveda’s management team at the Convention,
please submit a meeting request through the BIO One-on-One Partnering™
system or contact bd@tarvedatx.com.
About Tarveda Therapeutics®, Inc.
Tarveda Therapeutics is a clinical stage biopharmaceutical company that
is developing and discovering a new class of potent and selective
precision oncology medicines for the treatment of patients with solid
tumor malignancies. We are developing our proprietary Pentarins®
(miniature drug conjugates) to enhance the effectiveness of promising
anti-cancer payloads that have struggled without their selective
targeting to solid tumors. http://www.tarvedatx.com/
Contacts
Amanda Houlihan
MacDougall
781 235 3060
ahoulihan@macbiocom.com